Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: A meta-analytic investigation of randomized controlled trials

Schizophrenia Bulletin

Volumn 39, Issue 6, 2013, Pages 1230-1241

  Nitta, Masahiro ^a,b   Kishimoto, Taishiro ^a,c,d,e   Müller, Norbert ^f   Weiser, Mark ^g   Davidson, Michael ^g   Kane, John M ^a,d,e,h   Correll, Christoph U ^a,d,e,h  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^e FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^f UNIVERSITY OF MUNICH   (Germany)

^g TEL AVIV UNIVERSITY   (Israel)

^h ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Augmentation; Concomitant; Inflammation; Nonsteroidal anti inflammatory; Schizophrenia; Treatment resistance

Indexed keywords

ACETYLSALICYLIC ACID; AMISULPRIDE; CELECOXIB; CLOZAPINE; OLANZAPINE; PLACEBO; RISPERIDONE;

ADJUVANT THERAPY; ARTICLE; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFORMATION RETRIEVAL; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; TREATMENT DURATION;

AUGMENTATION; CONCOMITANT; INFLAMMATION; NONSTEROIDAL ANTI-INFLAMMATORY; SCHIZOPHRENIA; TREATMENT RESISTANCE;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84885194908     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbt070     Document Type: Article

References (64)

1. World Health Organization. Statistics on schizophrenia. 2010. http://www.who.int/mental-health/management/schizophrenia/en/index.html. Accessed May 9, 2013.
2. Kane JM, Correll CU. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry. 2010;71:1115-1124.
3. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry. 2009;14:429-447.
4. Essali A, Al Haj HN, Li C, Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev. 2009;1:CD000059.
5. Asenjo LC, Komossa K, Rummel-Kluge C et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;11:CD006633.
6. Correll CU. What are we looking for in new antipsychotics? J Clin Psychiatry. 2011;72(suppl 1):9-13.
7. Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev. 2009;3:CD006324.
8. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull. 2009;35:443-457.
9. Schwartz C, Volz A, Li C, Leucht S. Valproate for schizophrenia. Cochrane Database Syst Rev. 2008;3:CD004028.
10. Leucht S, Kissling W, McGrath J, White P. Carbamazepine for schizophrenia. Cochrane Database Syst Rev. 2007;3: CD001258.
11. Leucht S, Kissling W, McGrath J. Lithium for schizophrenia. Cochrane Database Syst Rev. 2007;3:CD003834.
12. Goff DC, Keefe R, Citrome L, et al. Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. J Clin Psychopharmacol. 2007;27:582-589. (Pubitemid 351339444)
13. Tiihonen J, Wahlbeck K, Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2009;109:10-14.
14. Dold M, Li C, Tardy M, Khorsand V, Gillies D, Leucht S. Benzodiazepines for schizophrenia. Cochrane Database Syst Rev. 2012;11:CD006391.
15. Shek E, Bardhan S, Cheine MV, Ahonen J, Wahlbeck K. Beta-blocker supplementation of standard drug treatment for Schizophrenia. Cochrane Database Syst Rev. 2001;3: CD000234.
16. Rummel C, Kissling W, Leucht S. Antidepressants for the negative symptoms of schizophrenia. Cochrane Database Syst Rev. 2006;3:CD005581.
17. Sepehry AA, Potvin S, Elie R, Stip E. Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. J Clin Psychiatry. 2007;68:604-610. (Pubitemid 46663044)
18. Singh SP, Singh V, Kar N, Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry. 2010;197: 174-179.
19. Ribeiz SR, Bassitt DP, Arrais JA, Avila R, Steffens DC, Bottino CM. Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature. CNS Drugs. 2010;24:303-317.
20. Irving CB, Mumby-Croft R, Joy LA. Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst Rev. 2006;3:CD001257.
21. Fusar-Poli P, Berger G. Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies. J Clin Psychopharmacol. 2012;32:179-185.
22. Saavedra-Velez C, Yusim A, Anbarasan D, Lindenmayer JP. Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review. J Clin Psychiatry. 2009;70:104-112.
23. Singh SP, Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs. 2011;25:859-885.
24. Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia. Cochrane Database Syst Rev. 2005;2:CD000076.
25. Hecht EM, Landy DC. Alpha-2 receptor antagonist add-on therapy in the treatment of schizophrenia; a meta-analysis. Schizophr Res. 2012;134:202-206.
26. Elias A, Kumar A. Testosterone for schizophrenia. Cochrane Database Syst Rev. 2007;3:CD006197.
27. Chua WL, de Izquierdo SA, Kulkarni J, Mortimer A. Estrogen for schizophrenia. Cochrane Database Syst Rev. 2005;4:CD004719.
28. Sommer IE, de Witte L, Begemann M, Kahn RS. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J Clin Psychiatry. 2012;73:414-419.
29. Gupta S, Kulhara P. What is schizophrenia: a neurodevelopmental or neurodegenerative disorder or a combination of both? A critical analysis. Indian J Psychiatry. 2010;52:21-27.
30. Rapoport JL, Giedd JN, Gogtay N. Neurodevelopmental model of schizophrenia: update 2012. Mol Psychiatry. 2012;17:1228-1238.
31. Gilmour G, Dix S, Fellini L, et al. NMDA receptors, cognition and schizophrenia-testing the validity of the NMDA receptor hypofunction hypothesis. Neuropharmacology. 2012;62: 1401-1412.
32. Terry AV Jr. Role of the central cholinergic system in the therapeutics of schizophrenia. Curr Neuropharmacol. 2008;6: 286-292.
33. Sander K, Kottke T, Stark H. Histamine H3 receptor antagonists go to clinics. Biol Pharm Bull. 2008;31:2163-2181.
34. Meltzer HY. Serotonergic mechanisms as targets for existing and novel antipsychotics. Handb Exp Pharmacol. 2012;212:87-124.
35. Ginovart N, Kapur S. Role of dopamine D(2) receptors for antipsychotic activity. Handb Exp Pharmacol. 2012;212:27-52.
36. Mulle JG. Schizophrenia genetics: progress, at last. Curr Opin Genet Dev. 2012;22:238-244.
37. Müller N, Schwarz MJ. Immune system and schizophrenia. Curr Immunol Rev. 2010;6:213-220.
38. Richard MD, Brahm NC. Schizophrenia and the immune system: pathophysiology, prevention, and treatment. Am J Health Syst Pharm. 2012;69:757-766.
39. Dean B. Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies. Int J Neuropsychopharmacol. 2011;14:997-1012.
40. Meyer U. Anti-inflammatory signaling in schizophrenia. Brain Behav Immun. 2011;25:1507-1518.
41. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70: 663-671.
42. Miller BJ, Culpepper N, Rapaport MH. C-reactive protein levels in schizophrenia. Clin Schizophr Relat Psychoses. 2013;1-22.
43. Bayer TA, Buslei R, Havas L, Falkai P. Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci Lett. 1999;271:126-128. (Pubitemid 29400683)
44. Radewicz K, Garey LJ, Gentleman SM, Reynolds R. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J Neuropathol Exp Neurol. 2000;59:137-150. (Pubitemid 30106470)
45. van Berckel BN, Bossong MG, Boellaard R, et al. Microglia activation in recent-onset schizophrenia: a quantitative ®-[11C] PK11195 positron emission tomography study. Biol Psychiatry. 2008;64:820-822.
46. Doorduin J, de Vries EF, Willemsen AT, de Groot JC, Dierckx RA, Klein HC. Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med. 2009;50:1801-1807.
47. Keller WR, Kum LM, Wehring HJ, Koola MM, Buchanan RW, Kelly DL. A review of anti-inflammatory agents for symptoms of schizophrenia. J Psychopharmacol. 2013;27:337-342.
48. Green GA. Understanding NSAIDs: from aspirin to COX-2. Clin Cornerstone. 2001;3:50-60.
49. Rouzer CA, Marnett LJ. Cyclooxygenases: structural and functional insights. J Lipid Res. 2009;50:S29-S34.
50. Takeuchi K. Pathogenesis of NSAID-induced gastric damage: importance of cyclooxygenase inhibition and gastric hypermotility. World J Gastroenterol. 2012;18:2147-2160.
51. Müller N, Riedel M, Scheppach C, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry. 2002;159: 1029-1034. (Pubitemid 34586950)
52. Müller N, Ulmschneider M, Scheppach C, et al. COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. Eur Arch Psychiatry Clin Neurosci. 2004;254:14-22. (Pubitemid 39310544)
53. Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmadpour O, Dolnak D. Celecoxib augmentation of continuously ill patients with schizophrenia. Biol Psychiatry. 2005;57:1594-1596. (Pubitemid 40805391)
54. Rappard F, Müller N. Celecoxib add-on therapy does not have beneficial antipsychotic effects over risperidone alone in schizophrenia. Neuropsychopharmacology. 2004;29:S222.
55. Müller N, Riedel M, Dehning S, et al. Is the therapeutic effect of celecoxib in schizophrenia depending from duration of disease? Neuropsychopharmacology. 2004;29:S176.
56. Weiser M, Burshtein S, Fodoreanu L, et al. A randomized trial administering aspirin, minocycline or pramipexole vs placebo as add-on to antipsychotics in patients with schizophrenia or schizoaffecive disorder. Neuropsychopharmacology. 2012;38:S351.
57. Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebocontrolled trial. Schizophr Res. 2007;90:179-185. (Pubitemid 46177578)
58. Laan W, Grobbee DE, Selten JP, Heijnen CJ, Kahn RS, Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2010;71:520-527.
59. Müller N, Krause D, Dehning S, et al. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res. 2010;121:118-124.
60. Na KS, Jung HY, Kim YK. The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. November 1, 2012; doi:10.1016/j.pnpbp.2012.10.022.
61. Shader RI. Too good to be true? Aspirin and schizophrenia. J Clin Psychopharmacol. 2012;32:583-584.
62. Tang B, Capitao C, Dean B, Thomas EA. Differential ageand disease-related effects on the expression of genes related to the arachidonic acid signaling pathway in schizophrenia. Psychiatry Res. 2012;196:201-206.
63. García-Bueno B, Bioque M, Mac-Dowell KS, et al. Pro-/antiinflammatory dysregulation in patients with first episode of psychosis: toward an integrative inflammatory hypothesis of schizophrenia. Schizophr Bull. March 13, 2013; doi:10.1093/molbev/msg013.
64. Correll CU, Hauser M, Auther AM, Cornblatt BA. Research in people with psychosis risk syndrome: a review of the current evidence and future directions. J Child Psychol Psychiatry. 2010;51:390-431.